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Abstract: Accumulating evidence suggests a potential role of dietary protein among nutritional
factors interfering with the regulation of blood pressure. Dietary protein source (plant versus
animal protein), and especially, protein composition in terms of amino acids has been postulated
to interfere with mechanisms underlying the development of hypertension. Recently, mounting
interest has been directed at amino acids in hypertension focusing on habitual dietary intake and
their circulating levels regardless of single amino acid dietary supplementation. The aim of the
present review was to summarize epidemiological evidence concerning the connection between
amino acids and hypertension. Due to the large variability in methodologies used for assessing amino
acid levels and heterogeneity in the results obtained, it was not possible to draw robust conclusions.
Indeed, some classes of amino acids or individual amino acids showed non-causative association
with blood pressure as well as the incidence of hypertension, but the evidence was far from being
conclusive. Further research should be prompted for a thorough understanding of amino acid effects
and synergistic actions of different amino acid classes on blood pressure regulation.
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1. Introduction
According to recent epidemiological projections, the global burden of hypertension is associated
with a remarkable increase in poor health outcomes. The global age-standardized prevalence of
elevated blood pressure was 24.1% in men and 20.1% in women in 2015 [1]. The overall global
prevalence of hypertension is expected to increase by 15–20% by 2025. Based on the Global Burden of
Disease report, in 2015 a 1.4 fold increase was detected in mortality and disability-adjusted life years
(DALYs) due to the presence of elevated systolic blood pressure since 1990 [2].
The association between hypertension and dietary and lifestyle factors is well established,
with excess weight, lack of sufficient physical activity, and high sodium intake acknowledged as the
main contributors [3]. Nonetheless, dietary interventions play a pivotal role in the extant treatment
strategies for hypertension [4].
Growing interest has been directed to the potential effect of specific nutrients on blood pressure.
Association between dietary protein and hypertension has been described, with a high-protein diet
exerting beneficial effects on blood pressure [5]; however, the inverse relationship between dietary
protein intake and blood pressure described in short-term studies appears to be weakened when
considering longer study duration [6]. One potential mechanism for anti-hypertensive effects connected
to elevated protein intake may be represented by the replacement of other macronutrients, mainly
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carbohydrates: if hypotensive effects are attributable to increased protein intake per se or to the
concomitant reduction in the proportions of fat and carbohydrate is still unclear [6].
Data regarding the potential effect of the type (plant versus animal source) of dietary protein
and blood pressure are not consistent [7]. Evidence from observational studies suggesting a favorable
effect on blood pressure due to the vegetable protein intake is not further supported by a meta-analysis
including data from forty randomized controlled studies [8], with no differences on blood pressure
levels related to dietary protein source. Different protein amino acid compositions, and thus, amino
acid intake could be the reason for such discrepant results. It is the case of soy protein, a largely
investigated source of vegetable protein, in which some amino acids with antihypertensive properties
are abundant (i.e., arginine, and cysteine) [9]. Furthermore, amino acids as part of bioactive peptides
derived from food proteins may also be relevant in blood pressure regulation through the inhibition of
angiotensin converting enzymes [10]. In recent years, several studies have focused on amino acids and
hypertension, with conclusive evidence yet to be established.
The aim of the present review is to summarize epidemiological evidence concerning the connection
between amino acids and hypertension.
2. Methods
Relevant peer-reviewed journal articles published in English were identified in the MEDLINE
database (the last search was conducted on 31 January 2019); different combinations of the following
search terms were used: “amino acids”, “hypertension”, and “blood pressure”. Bibliographic references
from eligible articles were reviewed for selection of any additional studies.
Also, the following exclusion criteria were used: any articles concerning secondary hypertension
or central hypertension; any paper evaluating inherited disorders of amino acid metabolism; any study
regarding hepatic, renal, or musculoskeletal diseases; any article based on amino acid supplementation;
any study assessing amino acid derivatives; any study carried out in children and adolescents; and any
study conducted in animals. Review articles, letters in response to published articles, editorials,
commentaries, and conference abstracts were excluded.
3. Results
A total of seventeen studies were included. Study characteristics, study participants, amino acids
investigated, and main outcomes are summarized in Table 1. Ten out of seventeen studies evaluated
dietary amino acid intake based on different dietary recall methods (e.g., food-frequency questionnaire,
3 day food diary, 4 day dietary record, 24 h dietary recall, and cross-check dietary history method).
In six studies, either plasma or serum amino acid concentrations were assessed, and just one study
considered urinary amino acids. In one study, the levels of amino acids in the cerebrospinal fluid
were also assessed. Three studies relied on principal component analysis. A marked variability was
observed in terms of the number and groups of amino acids investigated, varying from one single
amino acid to the calculation of a ratio among different amino acids. Ten out of seventeen studies were
cross-sectional, six studies had a prospective design (though in the study by Venho et al. [11], only data
at the baseline were considered), and in one study, both the cross-sectional and the prospective analyses
were performed [12]. In longitudinal studies, the longest duration of follow-up was 10 years.
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Table 1. Study characteristics and main findings.
Authors Year Study Participants (n)and Study Design Ethnicity
Age
(Year) *
Amino Acids
(Dietary or Biological Fluid Analysis) Main Findings
Altorf-van der
Kuil W et al. [12] 2013
3086 men and women
(cross-sectional analysis) +
1810 men and women
(prospective analysis, 6 year
follow-up)
Dutch 66 ± 7 Glutamic acid, Arginine, cysteine, Lysine, Tyrosine (FFQ)
A higher intake of Tyr (∼0.3% of protein) was related to a 2.4 mm Hg lower SBP
(p-trend = 0.05) but not to DBP (p = 0.35). The other AA were not significantly
associated with BP levels in a cross-sectional analysis. None of the AA were
associated with incident hypertension (HR: 0.81–1.18; p-trend> 0.2).
Cheng Y et al. [13] 2018
103 men and women
DASH-Sodium
trial—considering only the arm
on a US diet
(cross-sectional study)
US-American 49 ± 10 Urinary AAs
Significant positive associations with SBP for urinary cysteine (p = 0.008),
Cit (p = 0.003), and Lys (p = 0.009); significant positive associations with DBP
for urinary cystine (p = 0.005) but not the other metabolites.
Hu W et al. [14] 2016
1302 men and women Huai’an
Diabetes Prevention Program
(cross-sectional study)
Chinese 40–79 Serum BCAAs (Val, Ile, and Leu) No significant correlation between either single BCAAs or total BCAAs, SBP,and DBP.
Jennings A
et al. [15] 2016
1997 female twins
Twin-UK cohort
(cross-sectional study)
British 41.7 ± 12.1 Dietary BCAA (FFQ)
Higher BCAA intake was also associated with significantly lower SBP
(Q5−Q1 = −2.3 mmHg, p-trend 0.01) comparing those in the highest and lowest
quintiles of intake. Lower prevalence ratio for hypertension in the highest
versus lowest quintile of BCAA intake (p = 0.02).
Ntzouvani A
et al. [16] 2017
100 men
(cross-sectional study) Greek 54.6 ± 8.9
Five AA patterns by PCA: Factor 1: BCAAs and AAAs,
glutamic and aspartic acid, Ala, Lys, and Met; Factor 2:
Gln, Gly, Ser, Asn, Thr, Orn, Lys, His, and Pro; Factor 3:
total homocysteine, cystathionine, creatinine,
trimethyllysine, methylmalonic acid, Pro and kynurenine;
Factor 4: betaine, choline, SDMA, dimethylglycine, and
creatinine; Factor 5: Arg, TMAO, Orn and Met. (plasma)
Factor 2 was negatively associated with SBP (r = −0.296, p ≤ 0.005).
Ogawa M
et al. [17] 1985
12 normotensive subjects and
12 patients with essential
hypertension under nutritional
control after at least 10 days of
standard hospital diet
(cross-sectional study)
Japanese 23–70 Plasma taurine, Ser, Met (sulfur AAs)(plasma and csf)
Plasma taurine, Ser, Met, and Thr were significantly lower in patients with
essential hypertension than in normotensive patients. The levels of plasma
taurine, Ser, Met, and total sulfur AAs correlated inversely to SBP. No difference
was observed in the CSF levels of free AA in normotensive and
hypertensive patients.
Oomen CM
et al. [18] 2000
806 men
The Zutphen Elderly Study
(prospective cohort study, 10
year follow-up)
Dutch 64–84 Dietary arginine (cross-check dietary history method) Non-significant lower SBP of approximately 2 mmHg with a 2.5 g/day higherArg intake (p = 0.25).
Siomakajlo M
et al. [19] 2017
263 men
(cross-sectional study) Polish 36–60
BCAAs, Phe, and AAAs: 2 factors by PCA: Factor 1:
BCAAs—Leu, Ile, Val-, and Phe; Factor 2: Tyr and Trp
(plasma)
Significant positive associations between Factor 1 and SBP (r = 0.15, 95% CI:
0.01; 0.3), and Factor 1 and
DBP (r = 0.17, 95% CI: 0.03; 0.33).
Stamler J et al. [20] 2009 4680 men and women(cross-sectional study)
Chinese, Japanese,
British,
and US-American
40–59 Glutamic acid (24-h dietary recall)
Glutamic acid intake (as percentage of total protein) higher by 2 SD
corresponded to lower DBP (z-score −2.15 to −3.57) and SBP
(z-score −2.21 to −3.66).
Stamler J et al. [21] 2013
4680 men and women
INTERMAP study
(cross-sectional study)
Chinese, Japanese,
British,
and US-American
40–59 Glycine (24-h dietary recall)
Estimated average BP differences associated with a 2-SD higher Gly intake
(0.71 g/24 h) were 2.0–3.0 mm Hg systolic BP (z = 2.97–4.32) stronger in Western
than in East Asian participants.
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Table 1. Cont.
Authors Year Study Participants (n)and Study Design Ethnicity
Age
(Year) *
Amino Acids
(Dietary or Biological Fluid Analysis) Main Findings
Teymoori F
et al. [22] 2019
4288 men and women
(prospective analysis, 3.1 year
follow-up)
Iranian 39.7 ± 12.8 Aromatic amino acids (FFQ)
The adjusted OR of hypertension for percentage of AAAs from total protein
intake was 1.63 (95% CI, 1.06–2.50; p = 0.03) when comparing the highest
quartile to the lowest. A positive relationship was observed between the highest
versus the lowest quartile Phe intake (OR = 1.66; 95% CI, 1.14–2.47; p = 0.03).
No significant association of Tyr and Trp intakes with hypertension risk.
Teymoori F
et al. [23] 2017
4288 men and women
(prospective analysis, 3.1 year
follow-up)
Iranian 39.7 ± 12.8
Three AA patterns by PCA: 1st pattern: Branched chain
AAs, aromatic AAs, and Pro. 2nd pattern: acidic AAs, and
proline. 3rd pattern: sulfuric AAs, and small AAs (Gly and
Ala) (FFQ)
The OR for incidence of hypertension of the highest quartile score of the first
pattern was 1.83 (95% CI: 1.21–2.77, p for trend = 0.002), compared to the lowest.
For the 2nd and 3rd patterns of dietary AA intake, no significant association
with incident hypertension was found, although the 3rd pattern did have a
slight tendency to reduce the risk of hypertension (OR = 0.81; 95% CI: 0.65–1.16,
p for trend = 0.20).
Teymoori F
et al. [24] 2018
4288 men and women
(prospective analysis, 3.1 years
follow-up)
Iranian 39.7 ± 12.8 AA ratios of Leu.Ser/Thr.Trp, Leu/Trp, Leu/Thr, and Ser/Thr(FFQ)
The OR of the highest quartile of dietary Leu.Ser/Thr.Trp intake was 1.48 (95%
CI: 1.04–2.09, p for trend: 0.02), compared with the lowest one. The OR of
hypertension in the highest, compared with the lowest quartile of the Leu/Thr
ratio (2.19 versus 2.02) was 1.46 (1.01–2.12), p for trend = 0.07.
Tuttle KR
et al. [25] 2012
92 men and women
THIS-DIET study
(nested cohort, prospective
analysis, 2 year follow-up)
95% White 59 ± 9 Methionine, alanine, threonine, histidine.(3-day food diary)
Met and Ala were positively associated with higher SBP (OR (95% CI): 1.29
(1.14–1.46), p < 0.001, and 1.17 (1.05–1.30), p = 0.005) and higher DBP (OR (95%
CI): 1.21 (1.05–1.39), p = 0.007, and 1.22 (1.07–1.38), p = 0.002).
Thr and His were inversely associated with SBP (OR (95% CI): 0.84 (0.74–0.96),
p = 0.01, and 0.92 (0.86–1.00), p = 0.04) and DBP (His only: OR (95% CI): 0.89
(0.82–0.97), p = 0.01)
Venho B et al. [11] 2002
1981 men
The Kuopio Ischaemic Heart
Disease Risk Factor Study
(KIHD)
(prospective cohort study,
dietary arginine assessment
just at baseline)
Finnish 52.3 ± 5.3
Total dietary arginine, animal-derived arginine,
plant-derived arginine
(4-day dietary record)
The regression coefficients between SBP and the intake of total, animal-derived
and plant-derived Arg were 0.01 (p = 0.674), <0.01 (p = 0.931), and 0.02
(p = 0.420), respectively. The regression coefficients between DBP and the intake
of total, animal-derived, and plant-derived Arg were <0.01 (p = 0.746), 0.01
(p = 0.831), and <0.03 (p = 0.195), respectively.
Yamaguchi N
et al. [26] 2017
8589 men and women
(cross-sectional study) Japanese >20
19 plasma free amino acids were measured: Ala, Arg, Asn,
Cit, Gln, Gly, His, Ile, Leu, Lys, Met, Orn, Phe, Pro, Ser, Thr,
Trp, Tyr, and Val
BCAAs and AAAs showed moderately positive correlation with SBP and DBP.
Yang R et al. [27] 2014 272 men and 200 women(cross-sectional study) Chinese 70.1 ± 6.6 Serum BCAAs (Val, Ile, and Leu) and AAAs (Tyr and Phe)
Positive correlations between total AAAs and DBP (r = 0.127), and total BCAAs
and DBP (r = 0.197) (all p < 0.05) as well as Val and SBP (p < 0.05). All single
AAAs and single BCAA were positively correlated with DBP (all p < 0.05).
Legend: BP: blood pressure; CSF: cerebrospinal fluid; SBP: systolic blood pressure; DBP: diastolic blood pressure; DASH: Dietary Approaches to Stop Hypertension; AA: amino acid;
AAAs: aromatic amino acids; BCAAs: branched chain amino acids; PCA: principal component analysis; FFQ: food frequency questionnaire; Ala: alanine; Arg: arginine; Asp: asparagine;
Cit: citrulline; Gln: glutamine; Gly: glycine; His: histidine; Ile: isoleucine; Leu: leucine; Lys: lysine; Met: methionine; Orn: ornithine; Phe: phenylalanine; Pro: proline; Ser: serine; SDMA:
symmetric dimethylarginine; Thr: threonine; TMAO: trimethylamine N-oxide; Trp: tryptophane; Tyr: tyrosine; Val: valine. SD: standard deviation; * Age expressed as mean ± SD, or age
range when mean age of total participants was not clearly stated.
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4. Discussion
The present review article provides evidence concerning the connections between amino acids and
hypertension, focusing on associations between either blood pressure levels or risk of hypertension,
and dietary amino acids or amino acid levels in biological fluids.
Only the study by Stamler et al. [20] reported a favorable relationship between dietary glutamic
acid and blood pressure, showing that an elevated dietary intake of glutamic acid was associated
with lower values of both systolic and diastolic blood pressure. This finding is not in accordance
with results from a Dutch study describing no association between dietary glutamic acid either blood
pressure levels or incidence of hypertension [12]. Vegetable proteins are especially rich in glutamic
acids. Glutamate is included in the glutathione molecule, with potential antioxidant effects improving
blood pressure homeostasis [28]. Ethnicity-related differences in dietary sources of glutamic acid may
explain those conflicting observations: in the INTERMAP study the association between glutamic
acid and reduced blood pressure was ascribed to the elevated presence of glutamic acid in vegetable
protein, in line with prior evidence indicating a lowering effect of plant protein on blood pressure [20].
Nonetheless, a more recent meta-analysis by Rebholz et al. [8] did not support a different association of
animal versus plant protein with blood pressure.
Regarding tyrosine, results are conflicting: in the Rotterdam study [12], a cross-sectional analysis
revealed that a high dietary intake of tyrosine was related to lower systolic blood pressure (though results
were statistically just marginally significant when considering quartiles of tyrosine intake, but they
become statistically significant when considering tyrosine intake as a continuous variable), but no
relationship emerged between dietary tyrosine and diastolic blood pressure. However, no association
with the incidence of hypertension was described in findings from prospective analysis after a 6
year follow-up.
Tyrosine effects on hypertension were also evaluated in another study investigating all aromatic
amino acids [24] in an Iranian adult study cohort: dietary tyrosine, as well as dietary tryptophan, did not
show any association with incident hypertension after a 3.1 year follow-up. Just phenylalanine intake in
the highest quartile was associated to significant increased risk of hypertension compared to the lowest
quartile. Nonetheless, when considered globally, high total dietary aromatic amino acid intake exhibited
a positive significant association with increased risk of incident hypertension [19,22,26,27]. In a Polish
observational study assessing plasma amino acid levels, principal component analysis identified
phenylalanine in a separated cluster from tyrosine and tryptophan [19]. Tyrosine acts as a precursor for
norepinephrine synthesis, therefore, it can modulate norepinephrine levels and affect the sympathetic
tone on the vasculature. Findings from animal studies revealed that tyrosine administration in rats
lowered blood pressure through central catecholamine action on alpha-receptors [29,30]. However,
data from rodents were not confirmed in hypertensive adults undergoing chronic dietary tyrosine
supplementation [31]. The majority of phenylalanine is converted to tyrosine, and effects on blood
pressure are potentially due to the changes in tyrosine levels. However, phenylalanine per se can interfere
with tetrahydrobiopterin (BH4) production, a cofactor for aromatic amino acid hydroxylation, involved
in the relaxation of the endothelium [32]. In the presence of the high availability of aromatic amino
acids, the oxidation of BH4 may result in alterations of its vasoactive properties with detrimental effects
on the endothelium [33]. Tryptophan is a precursor for the synthesis of serotonin (5-hydroxytryptamine,
5-HT), a monoaminergic neurotransmitter. Serotonin receptors are present on adrenergic nerves at
the level of the sympathetic–vascular junction, potentially explaining the mechanism underlying the
influence of 5-HT on the vascular tone [34]. Administration of l-tryptophan induced a reduction
in blood pressure in animals [35], and analogous short-term effects were described in hypertensive
patients but not in normotensive controls [36]. However, derangements of 5-HT metabolism have been
shown in hypertensive patients, and in the long-term, tryptophan effects on blood pressure are unclear.
These reasons may explain the lack of association of habitual dietary intake or circulating tryptophan
with blood pressure related outcomes [37]. Moreover, tryptophan-containing peptides obtained from
enzymatic hydrolysis of food protein have been shown to interfere with the renin–angiotensin axis
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inhibiting angiotensin-converting enzymes, though further evidence from human studies is needed [38].
Plasma phenylalanine, together with branched chain amino acids (BCAAs) in the same cluster, showed
a positive association with both systolic and diastolic blood pressure, whereas no association was
found with blood pressure when the other cluster, including the two remaining aromatic amino acids,
was taken into account.
Dietary BCAAs clustered with aromatic amino acids (AAAs), and proline based on principal
component analysis in a longitudinal study conducted in an Iranian cohort, showed a positive
association with incidence of hypertension [23]. Analogous findings of a positive relationship between
BCAAs and AAAs emerged in two Asian studies [26,27]. In the TwinUK cohort, dietary BCAAs were
associated with decreased risk of hypertension [15], whereas no relationship was observed in a Chinese
study considering serum BCAA levels [14]. In one study taking into account the ratio between different
dietary amino acids, the leucine–serine/threonine–tryptophan ratio results were significantly positively
associated with the risk of hypertension [22].
Branched chain amino acid concentrations in biological fluids (serum/plasma) were positively
associated with high blood pressure, though data were discrepant in some studies based on dietary
records. Plenty of studies indicated that alterations in BCAA metabolism, leading to the accumulation
of BCAAs and their byproducts, are linked to remarkable metabolic derangements such as insulin
resistance, the latter being associated with increased risk of hypertension [39,40]. Furthermore,
BCAA ingestion was able to reduce brain tryptophan and tyrosine uptake, affecting serotonin and
catecholamine synthesis with consequences on central blood pressure regulation [41,42]. Nonetheless,
BCAA effects on blood pressure may be counterbalanced in the presence of other nutrients: whey protein
is rich in both BCAAs and lactokinins, the latter with inhibiting properties on the angiotensin-converting
enzyme; thus, ingestion of whey protein may induce opposite effects on hypertension mediated by
BCAAs and lactokinins [43]. Interestingly, AAAs and BCAAs have hydrophobic or bulky residues that
can be relevant for the binding of bioactive peptides to the angiotensin-converting enzyme which is
crucial in blood pressure control [44].
Concerning dietary glycine, findings from the INTERMAP study were not in line with other
studies including glycine in factors obtained by principal component analysis [16,21,23].
In the INTERMAP study [21], dietary intake of glycine (expressed as a percentage of total protein
and based on 24 h dietary recall) was positively associated with both systolic and diastolic blood
pressure. Conversely, in a Greek study, plasma glycine levels—clustering with glutamine, serine,
asparagine, threonine, lysine, histidine, and proline in the principal component analysis—showed a
negative relationship with systolic blood pressure [16]. Also, in another study, the principal component
analysis pattern encompassing glycine, sulfur amino acids, and alanine, tended to be associated to a
diminished risk of hypertension [23]. An inverse correlation was observed between systolic blood
pressure and sulfur amino acids in plasma, but not in cerebrospinal fluid, in a small Japanese cohort [17].
Stamler et al. [21] postulated that dietary glycine intake was positively associated with blood pressure,
as glycine is abundant in animal-derived protein and meat consumption may be a dietary factor
for elevated blood pressure. Conversely, the opposite findings may be supported by the important
role played by glycine in reducing oxidative stress, favoring nitric oxide action; moreover, glycine is
involved in the synthesis of structural protein, such as elastin; alterations in elastin formation have
been connected to impaired elastic properties of vessels, a remarkable aspect in the pathogenesis of
hypertension [45].
Dietary alanine showed a positive relation to blood pressure in the INTERMAP study (expressed
as percentage of total protein intake) and in a nested cohort within the THIS-DIET study (as daily
intake in absolute value) [21,25].
With respect to methionine, results based on dietary records [25] were in disagreement with
findings from plasma amino acid levels [17]. Elevated dietary methionine intake was associated
with augmented systolic and diastolic blood pressure [25]. Methionine is an essential amino acid;
among its metabolic byproducts, homocysteine, when elevated, is well known for its ability to influence
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endothelial function inducing the production of asymmetrical dimethylarginine (ADMA), which in
turn, can inhibit the synthesis of nitric oxide [46]. Thus, methionine effects on blood pressure appear to
be indirect and mediated by the increase in homocysteine levels, as shown in studies relying on dietary
supplementation with methionine in animals and humans [47,48].
Several amino acids interfere with vascular physiology; among them, arginine is well known
to have relevant vasogenic properties [49]. Despite a wealth of studies demonstrating the beneficial
effects from dietary supplementation with l-arginine including lowering both systolic and diastolic
blood pressure levels [50,51], studies focusing on dietary arginine considering only a usual diet,
excluding supraphysiological intake through dietary supplementation, did not support any association
between this amino acid and blood pressure [11,18]. In middle-aged men participating in the Kuopio
Ischaemic Heart Disease Risk Factor Study (KIHD), no association was found between dietary arginine
and blood pressure levels, regardless of the dietary source (either plant-derived or animal-derived
arginine) [11]. Similarly, dietary arginine did not associate with blood pressure in a Dutch elderly male
population [18].
In the only study assessing urinary amino acids, a positive association was described between
urinary cysteine, citrulline, and lysine and systolic blood pressure, and between urinary cysteine and
diastolic blood pressure [13]. These data regarding urinary cysteine, as well as the lack of association
for dietary cysteine and blood pressure [12] are in contrast with evidence showing antihypertensive
effects mediated by cysteine through its free sulfhydryl group. The majority of studies on cysteine were
based on supplementation with its stable analogue N-acetyl-cysteine [52]. Cysteine is able to modulate
blood pressure by decreasing oxidative stress, increasing nitric oxide bioavailability, and ameliorating
insulin sensitivity [52]. In addition, cysteine is part of the tripeptide glutathione with glutamic acid
and glycine. Glutathione is in turn well known for its antioxidant ability with additional beneficial
consequences on blood pressure regulation [52].
5. Conclusions
Due to the large variability in methodologies used for assessing amino acid levels and heterogeneity
in results obtained, it was not possible to draw robust conclusions. In fact, the use of any type of
dietary records was affected by under- or overreporting [53,54]. Data based on direct measurements in
plasma and other biological fluids are more reliable, though they can be affected by derangements in
metabolic cascades leading to alterations in amino acid metabolic byproducts.
Further research should be prompted for a thorough understanding of the synergistic actions
of different amino acid classes on blood pressure regulation. In addition, the interplay between gut
microbiota and amino acid metabolism in hypertension [55] deserves future investigation.
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